Stay updated with breaking news from Deena Beasley. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
An FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about safety of the treatment for patients with early-stage disease.
-The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen's tarlatamab, a targeted immunotherapy for adults in the advanced stages of hard-to-treat small...
The U.S. Food and Drug Administration granted accelerated approval to tarlatamab, Amgen's targeted immunotherapy for treating adults with advanced small cell lung cancer that has worsened despite...
By Deena Beasley (Reuters) - Amgen reported a slightly lower first-quarter profit on Thursday, citing higher operating and interest expense from its recent acquisition of rare disease drugmaker Horizon Therapeutics, partially offset by double-digit...
By Deena Beasley (Reuters) -Amgen on Thursday said it was very encouraged after completing an interim analysis of its mid-stage study of experimental ...